| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Barbara Savoldo | Q109983471 |
| P2093 | author name string | Leslie E Huye | |
| Serena Kimi Perna | |||
| P2860 | cites work | Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. | Q53247401 |
| High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial | Q60685639 | ||
| Non-Hodgkin lymphoma | Q84629067 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma | Q28537688 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells | Q29620717 | ||
| Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 | Q33749635 | ||
| Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. | Q33828575 | ||
| Current concepts in the diagnosis and management of cytokine release syndrome | Q33886879 | ||
| Managing cytokine release syndrome associated with novel T cell-engaging therapies. | Q33993517 | ||
| Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma | Q34018782 | ||
| Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. | Q34273968 | ||
| Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? | Q34317117 | ||
| Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 | Q34360292 | ||
| Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation | Q34687563 | ||
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients | Q34876434 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity | Q35142912 | ||
| Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. | Q35586880 | ||
| T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells | Q35848840 | ||
| Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype | Q35849686 | ||
| CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results | Q35953372 | ||
| Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer | Q36059593 | ||
| Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans | Q36060239 | ||
| Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors | Q36070000 | ||
| Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale | Q36475411 | ||
| Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells | Q36868712 | ||
| Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients | Q36919619 | ||
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. | Q37095348 | ||
| Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies | Q37178611 | ||
| Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells | Q37389364 | ||
| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation | Q37390239 | ||
| Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. | Q37599478 | ||
| Antibody-modified T cells: CARs take the front seat for hematologic malignancies | Q37723469 | ||
| Artificial antigen-presenting cells for use in adoptive immunotherapy | Q37778699 | ||
| The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings | Q37824456 | ||
| Lymphoma complicating primary immunodeficiency syndromes | Q38004723 | ||
| T-cell therapy in the treatment of post-transplant lymphoproliferative disease | Q38026758 | ||
| Recent advances in the treatment of non-Hodgkin's lymphomas. | Q38109135 | ||
| Relapsed and refractory aggressive NHL: time for a change | Q38120117 | ||
| Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration | Q39150753 | ||
| Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma | Q39398399 | ||
| Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? | Q43833425 | ||
| Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation | Q44618759 | ||
| Non-Hodgkin's lymphomas, version 1.2013. | Q45276579 | ||
| Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation | Q45780110 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 55-63 | |
| P577 | publication date | 2015-03-19 | |
| P1433 | published in | ImmunoTargets and therapy | Q27724782 |
| P1476 | title | Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy | |
| P478 | volume | 4 |
| Q89669654 | Cellular Immunotherapy in Lymphoma: Beyond CART Cells | cites work | P2860 |
Search more.